point of care
The company will use the funds to enhance the development of its AI capabilities and for commercial growth.
The pharma giant will also pay $55 million to fund the point-of-care diagnostics platform until the acquisition closes, which is expected to occur by mid-2024.
Leveraging evidence-based knowledge in a meaningful way can help clinicians at the bedside during situations such as COVID-19, says Dr. Ian Chuang, chief medical officer for Elsevier's EMEALAAP Health business.
The company's complete blood count analyzer uses artificial intelligence to quickly measure biomarkers from a fingerstick or venous sample.